Co-Authors
This is a "connection" page, showing publications co-authored by Cristina Gervasoni and Dario Cattaneo.
Connection Strength
19.911
-
Comment on "Comparative Population Pharmacokinetics of Darunavir in SARS-CoV-2 Patients vs. HIV Patients: The Role of Interleukin-6". Clin Pharmacokinet. 2021 06; 60(6):829-831.
Score: 0.940
-
Drug-Drug Interactions and Prescription Appropriateness at Hospital Discharge: Experience with COVID-19 Patients. Drugs Aging. 2021 04; 38(4):341-346.
Score: 0.932
-
Prediction of lopinavir/ritonavir effectiveness in COVID-19 patients: a recall of basic pharmacology concepts. Eur J Clin Pharmacol. 2021 05; 77(5):791-792.
Score: 0.915
-
Clinical Features and Outcomes of Patients With Human Immunodeficiency Virus With COVID-19. Clin Infect Dis. 2020 11 19; 71(16):2276-2278.
Score: 0.914
-
Reply to Childs et al. Clin Infect Dis. 2020 11 05; 71(8):2023.
Score: 0.912
-
Drug-Drug Interactions and Prescription Appropriateness in Patients with COVID-19: A Retrospective Analysis from a Reference Hospital in Northern Italy. Drugs Aging. 2020 12; 37(12):925-933.
Score: 0.912
-
Pharmacokinetics and Pharmacodynamics of Cabotegravir, a Long-Acting HIV Integrase Strand Transfer Inhibitor. Eur J Drug Metab Pharmacokinet. 2019 Jun; 44(3):319-327.
Score: 0.826
-
Different effects of glucocorticoids on darunavir plasma concentrations. Eur J Clin Pharmacol. 2019 May; 75(5):733-735.
Score: 0.803
-
Management of Polypharmacy and Drug-Drug Interactions in HIV Patients: A 2-year Experience of a Multidisciplinary Outpatient Clinic AIDS Rev. 2019; 21(1):40-49.
Score: 0.802
-
Evaluation of the concentrations of psychotropic drugs in HIV-infected versus HIV-negative patients: Potential implications for clinical practice. World J Biol Psychiatry. 2020 10; 21(8):651-657.
Score: 0.787
-
Loss of Control of HIV Viremia With OTC Weight-Loss Drugs: A Call for Caution? Obesity (Silver Spring). 2018 08; 26(8):1251-1252.
Score: 0.779
-
How relevant are the drug-drug interactions between antiretroviral boosted-based regimens and calcium channel blockers in real life? J Antimicrob Chemother. 2018 08 01; 73(8):2271-2273.
Score: 0.779
-
Dolutegravir and metformin: a clinically relevant or just a pharmacokinetic interaction? AIDS. 2018 02 20; 32(4):532-533.
Score: 0.756
-
Psychoactive drugs and HIV: are we sure to treat our patients adequately? AIDS. 2018 01 02; 32(1):127-128.
Score: 0.749
-
The relevance of drug-drug interactions in clinical practice: the case of concomitant boosted protease inhibitors plus alpha-1 blocker administration. Antivir Ther. 2018; 23(5):467-469.
Score: 0.749
-
Effect of Cobicistat on Tenofovir Disoproxil Fumarate (TDF): What Is True for TAF May Also Be True for TDF. J Acquir Immune Defic Syndr. 2018 01 01; 77(1):86-92.
Score: 0.749
-
Generics for the Treatment of Hepatitis C in Monoinfected and HIV-coinfected Patients: Pros and Cons. AIDS Rev. 2017 Oct-Dec; 19(3):167-172.
Score: 0.736
-
Novel Antiretroviral Drugs in Patients with Renal Impairment: Clinical and Pharmacokinetic Considerations. Eur J Drug Metab Pharmacokinet. 2017 Aug; 42(4):559-572.
Score: 0.727
-
Effects of ritonavir and cobicistat on dolutegravir exposure: when the booster can make the difference. J Antimicrob Chemother. 2017 06 01; 72(6):1842-1844.
Score: 0.719
-
How Relevant is the Interaction Between Dolutegravir and Metformin in Real Life? J Acquir Immune Defic Syndr. 2017 05 01; 75(1):e24-e26.
Score: 0.715
-
Intolerance of dolutegravir-containing combination antiretroviral therapy: not just a pharmacokinetic drug interaction. AIDS. 2017 03 27; 31(6):867-868.
Score: 0.710
-
Dolutegravir plasma concentrations according to companion antiretroviral drug: unwanted drug interaction or desirable boosting effect? Antivir Ther. 2017; 22(4):353-356.
Score: 0.697
-
Preventing COVID-19 in assisted living facilities: An impossible task pending vaccination roll out. Prev Med Rep. 2021 Sep; 23:101471.
Score: 0.238
-
The importance of anamnesis in differential diagnosis: a case of SARS-CoV-2 and dengue virus co-infection. Infez Med. 2021 Mar 01; 29(1):114-116.
Score: 0.233
-
Immune deficiency is a risk factor for severe COVID-19 in people living with HIV. HIV Med. 2021 05; 22(5):372-378.
Score: 0.230
-
Lopinavir/ritonavir in COVID-19 patients: maybe yes, but at what dose? J Antimicrob Chemother. 2020 09 01; 75(9):2704-2706.
Score: 0.225
-
Does lopinavir really inhibit SARS-CoV-2? Pharmacol Res. 2020 08; 158:104898.
Score: 0.220
-
Darunavir does not prevent SARS-CoV-2 infection in HIV patients. Pharmacol Res. 2020 07; 157:104826.
Score: 0.219
-
Drug-induced liver steatosis in patients with HIV infection. Pharmacol Res. 2019 07; 145:104267.
Score: 0.205
-
Is it time to revise linezolid dose in elderly patients? Eur J Clin Pharmacol. 2017 Oct; 73(10):1335-1336.
Score: 0.181
-
The impact of gastrectomy on the pharmacokinetics of atazanavir and tenofovir. Eur J Clin Pharmacol. 2017 Jun; 73(6):789-790.
Score: 0.177
-
Pregnancy-related changes of antiretroviral pharmacokinetics: an argument for therapeutic drug monitoring. Antivir Ther. 2017; 22(4):361-363.
Score: 0.175
-
Early administration of lopinavir/ritonavir plus hydroxychloroquine does not alter the clinical course of SARS-CoV-2 infection: A retrospective cohort study. J Med Virol. 2021 03; 93(3):1421-1427.
Score: 0.057
-
Darunavir Population Pharmacokinetic Model Based on HIV Outpatient Data. Ther Drug Monit. 2019 02; 41(1):59-65.
Score: 0.050
-
Burden of Exposure to Potential Interactions Between Antiretroviral and Non-Antiretroviral Medications in a Population of HIV-Positive Patients Aged 50 Years or Older. J Acquir Immune Defic Syndr. 2018 06 01; 78(2):193-201.
Score: 0.048
-
Pharmacogenetics-based optimisation of atazanavir treatment: potential role of new genetic predictors. Drug Metab Pers Ther. 2017 05 24; 32(2):115-117.
Score: 0.045